Comparative Pharmacology
Head-to-head clinical analysis: RISEDRONATE SODIUM versus SKELID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISEDRONATE SODIUM versus SKELID.
RISEDRONATE SODIUM vs SKELID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
SKELID (tiludronate disodium) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity and recruitment.
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
400 mg (2 tablets) orally once daily, taken on an empty stomach at least 2 hours before or after food, for 2 hours with 8 oz plain water; avoid other beverages, food, and medications for 2 hours post-dose.
None Documented
None Documented
Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis.
Terminal elimination half-life: 10-12 hours (prolonged in renal impairment; no dose adjustment required for mild-moderate impairment but contraindicated in severe impairment [CrCl <30 mL/min])
Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible.
Renal: 50-60% unchanged drug; biliary/fecal: <5%
Category D/X
Category C
Bisphosphonate
Bisphosphonate